Metabolism in cancer cells differs from that in normal cells, but it is only recently that opportunities to specifically target these differences to develop novel anticancer drugs are being revealed. Jim Schnabel investigates new collaborations to harness this potential.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ROS homeostasis and metabolism: a critical liaison for cancer therapy
Experimental & Molecular Medicine Open Access 04 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Targeting tumour metabolism. Nat Rev Drug Discov 9, 503–504 (2010). https://doi.org/10.1038/nrd3215
Issue Date:
DOI: https://doi.org/10.1038/nrd3215
This article is cited by
-
Rethinking our approach to cancer metabolism to deliver patient benefit
British Journal of Cancer (2023)
-
ROS homeostasis and metabolism: a critical liaison for cancer therapy
Experimental & Molecular Medicine (2016)
-
Targeting tumour-supportive cellular machineries in anticancer drug development
Nature Reviews Drug Discovery (2014)
-
Synthesis, characterization, and biological studies of emissive rhenium–glutamine conjugates
JBIC Journal of Biological Inorganic Chemistry (2013)